🔎 Trials Near Me

Dachaigh › Aillse Prostata › Ohio

Sgrùdaidhean clionaigeach Aillse Prostata ann an Ohio

Tha 65 sgrùdaidhean airson Aillse Prostata a’ lorg phàirtichean aig làraichean ann an Ohio.

Bailtean ann an Ohio

Teacsa sgrùdaidh oifigeil (Beurla)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 45 gu 75 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06995898

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Gabrail Cancer Center Research, Canton
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 5 Dàmh 2026 · NCT07723248

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
A’ fastadhÌre 2
Aoisean 19 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06738303

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • Aultman Health Foundation, Canton
  • Ohio State University Comprehensive Cancer Center, Columbus
  • ProMedica Flower Hospital, Sylvania
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 2 Dàmh 2026 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • MetroHealth Medical Center, Cleveland
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 2 Dàmh 2026 · NCT07200830

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • MetroHealth Medical Center, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06632977

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • agus 44 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Strecker Cancer Center-Belpre, Belpre
  • Adena Regional Medical Center, Chillicothe
  • Ohio State University Comprehensive Cancer Center, Columbus
  • agus 22 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT03866382

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

  • University Hospitals Cleveland Medical Center, Cleveland
A’ fastadh
Aoisean 18 agus nas sine · Fir · Air ùrachadh 28 Sult 2026 · NCT06496256

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07319871

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 130 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07124000

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06136650

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 25 Sult 2026 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
  • TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
  • University Hospitals Cleveland Medical Center, Cleveland
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 24 Sult 2026 · NCT07028853

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
  • The Ohio State University, Columbus
  • Dayton Physicians LLC Dayton, Dayton
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 22 Sult 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Urology Group - Solaris Network, Cincinnati
  • Central Ohio Urology Group, Gahanna
A’ fastadhÌre 3
Aoisean 18 gu 100 · Fir · Air ùrachadh 22 Sult 2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 18 Sult 2026 · NCT06952803

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Sult 2026 · NCT06925737

Investigation of Impact of AI on Prostate Cancer Workflow

  • Cleveland Clinic Foundation, Cleveland
A’ fastadh
Aoisean 55 gu 80 · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT07084779

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 15 Sult 2026 · NCT07493512

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

  • University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 15 Sult 2026 · NCT06150417

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • University Hospitals Cleveland, Cleveland
A’ fastadh
Aoisean 18 agus nas sine · Fir · Air ùrachadh 14 Sult 2026 · NCT06511141

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • agus 27 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 10 Sult 2026 · NCT05946213

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  • Solaris Health - The Urology Group, Cincinnati
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 3 Sult 2026 · NCT07005154

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Cleveland
  • Research Site, Dayton
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 26 Lùna 2026 · NCT07611110

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 21 Lùna 2026 · NCT04221542

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  • The Ohio State University, Columbus
  • Taylor Cancer Research Center, Maumee
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 20 Lùna 2026 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 19 Lùna 2026 · NCT04423211

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
  • Cleveland Clinic, Cleveland
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05919264

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • University Hospitals Cleveland Medical Center, Cleveland
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 17 Lùna 2026 · NCT06842498

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • University of Cincinnati Medical Center, Cincinnati
  • The Ohio State University, Columbus
A’ fastadhÌre 1
Aoisean 18 gu 100 · Fir · Air ùrachadh 13 Lùna 2026 · NCT05519449

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

  • Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
A’ fastadh
Aoisean 19 agus nas sine · Fir · Air ùrachadh 6 Lùna 2026 · NCT05610852

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

  • The Ohio State University, Columbus
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 31 Iuch 2026 · NCT06613100

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

  • Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Fir · Air ùrachadh 14 Iuch 2026 · NCT05691465

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • agus 15 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Fir · Air ùrachadh 14 Iuch 2026 · NCT06592924

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  • The Ohio State University Comprehensive Cancer Center, Columbus
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Fir · Air ùrachadh 9 Iuch 2026 · NCT07103018

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

  • Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Fir · Air ùrachadh 7 Iuch 2026 · NCT07406282

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.